Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James E Signorovitch

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
Clinical and Experimental Rheumatology|March 25, 2017
Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real worldMin Yang, Philip J Galebach, James E Signorovitch, et al.
Radiology|September 18, 2008
Bladder cancer detection with CT urography in an Academic Medical CenterCheryl A Sadow, Stuart G Silverman, Michael P O'Leary, et al.
Journal of the American Academy of Dermatology|August 2, 2016
Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasisApril W Armstrong, Keith A Betts, Murali Sundaram, et al.
Journal of Medical Economics|August 29, 2014
Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western EuropeMario Campone, Hongbo Yang, Elizabeth Faust, et al.
Current Medical Research and Opinion|January 9, 2016
An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritisKeith A Betts, Jenny Griffith, Alan Friedman, et al.
Clinical Drug Investigation|August 9, 2011
Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trialsJames E Signorovitch, Eric Q Wu, Elyse Swallow, et al.
Therapeutics and Clinical Risk Management|August 14, 2018
Identifying a subpopulation with higher likelihoods of early response to treatment in a heterogeneous rare disease: a post hoc study of response to teduglutide for short bowel syndromeKristina S Chen, Jipan Xie, Wenxi Tang, et al.
Breast Cancer : Basic and Clinical Research|September 19, 2015
Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2- Metastatic Breast CancerYan Song, Yanni Hao, Alexander R Macalalad, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 7, 2018
Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized TrialsKim A Papp, Min Yang, Murali Sundaram, et al.
Journal of Comparative Effectiveness Research|July 11, 2015
Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infectionJames E Signorovitch, Keith A Betts, Yan Song, et al.
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
Clinical and Experimental Rheumatology|March 25, 2017
Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real worldMin Yang, Philip J Galebach, James E Signorovitch, et al.
Radiology|September 18, 2008
Bladder cancer detection with CT urography in an Academic Medical CenterCheryl A Sadow, Stuart G Silverman, Michael P O'Leary, et al.
Journal of the American Academy of Dermatology|August 2, 2016
Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasisApril W Armstrong, Keith A Betts, Murali Sundaram, et al.
Journal of Medical Economics|August 29, 2014
Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western EuropeMario Campone, Hongbo Yang, Elizabeth Faust, et al.
Current Medical Research and Opinion|January 9, 2016
An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritisKeith A Betts, Jenny Griffith, Alan Friedman, et al.
Clinical Drug Investigation|August 9, 2011
Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trialsJames E Signorovitch, Eric Q Wu, Elyse Swallow, et al.
Therapeutics and Clinical Risk Management|August 14, 2018
Identifying a subpopulation with higher likelihoods of early response to treatment in a heterogeneous rare disease: a post hoc study of response to teduglutide for short bowel syndromeKristina S Chen, Jipan Xie, Wenxi Tang, et al.
Breast Cancer : Basic and Clinical Research|September 19, 2015
Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2- Metastatic Breast CancerYan Song, Yanni Hao, Alexander R Macalalad, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 7, 2018
Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized TrialsKim A Papp, Min Yang, Murali Sundaram, et al.
Journal of Comparative Effectiveness Research|July 11, 2015
Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infectionJames E Signorovitch, Keith A Betts, Yan Song, et al.
Pageof 5